Sign in
CompletedPhase 2

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

Key facts

Who runs it
Bing Han
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
58 people enrolled
Started
19 Dec 2022
Ended
15 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Luspatercept
  • Cyclosporine
Record updated
16 September 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • age≥18 year-old
  • hemoglobin level between 60g/L~10 g/dL
  • newly diagnosed patients have at least one of the followings: #absolute neutrophil count <1.5×109/L, #platelet count < 30×109/L, # hemoglobin level < 100g/L
  • with normal baseline liver and kidney function
  • with no active infection; are not pregnant or nursing
  • agree to sign consent forms
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Who cannot take part

  • Patients received HSCT before
  • Have any concomitant malignancies within 5 years expect for local basal cell carcinoma of the skin
  • Evidence of a clonal hematologic bone marrow disorder (MDS, AML) on cytogenetics
  • Uncontrolled infection or bleeding with standard treatment
  • Allergic to luspatercept CsA or accessories
  • HIV, HCV or HBV active infection or liver cirrhosis or portal hypertension
  • Past history of thromboembolic event, heart attack or stroke (including anti-phospholipid antibody syndrome) and current use of anticoagulants
  • Patient with QTcF (Fridericia's QT correction formula) at screening <450 msec, or<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site, unstable angina pectoris, uncontrolled hypertension(>180/100mmHg)#pulmonary artery hypertension
  • Congenital aplastic anemia
  • Presence of chromosomal aberration
  • Presence with PNH clone ≥50%
  • Pregnant or nursing (lactating) woman
  • Have attended other clinical trials within 3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia. AA is divided into severe AA (SAA) and non-severe AA (NSAA) based on the degree of cytopenia. The first line therapy for SAA or transfusion dependent NSAA is either immunosuppression therapy (IST) or hematopoietic stem cell transplantation (HSCT). Little attention has been paid to patients with anemia but not transfusion dependent, whose quality of life is significantly impaired due to the anemia and other complications.

The 2 groups in the trial

  • efficiency and safety in luspatercept plus cyclosporineTreatment being tested

    luspatercept is at a dose of 1.0 mg per kilogram of body weight, administered subcutaneously every 3 weeks,and cyclosporine is at a dose of 3\~5mg/kg /day for at least 6 months.

    Treatment: Luspatercept and Cyclosporine

  • controll group in cyclosporine aloneExisting treatment, for comparison

    cyclosporine is at a dose of 3\~5mg/kg /day for at least 6 months.

    Treatment: Cyclosporine

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Case Controlled Clinical Trial Evaluating the Efficiency and Safety of Luspatercept Plus Cyclosporine Versus Cyclosporine in Newly Diagnosed Transfusion Independent Non-severe Aplastic Anemia (NSAA).
Publications
Record updated
16 September 2025